NYSE:BSXMedical Equipment
Boston Scientific (BSX) Faces Flat Watchman Revenue As Doctors Combine Heart Procedures
Boston Scientific’s Watchman heart device is increasingly being implanted during combined cardiac procedures instead of as a standalone treatment.
This shift in medical practice has reduced standalone Watchman procedure volumes and is expected to keep revenue for the product line roughly flat through Q3 2026.
The change reflects how doctors are rethinking procedure planning, with implications for Boston Scientific’s growth mix and product planning.
For investors watching Boston Scientific...